Background: Cardiovascular diseases (CVD) are the primary cause of morbidity and mortality among individuals with T2D, where cardiovascular risk tends to be primarily influenced by dyslipidemia. The present study assessed efficacy of Saroglitazar in patients with diabetic dyslipidemia. Materials & Methods: 84 patients with type II diabetes mellitus of both genders were selected. Patients were treated with Saroglitazar 4 mg once daily. All parameters such as serum fasting blood glucose, post-prandial blood glucose level (PPBG), glycated hemoglobin (HbA1c), blood urea, serum creatinine, S.G.O.T, S.G.P.T and lipid profile were determined at baseline, 12 weeks and 48 weeks.